- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01083511
Collection and Extraction of Respiratory Specimens
Collection & Extraction of Respiratory Specimens for the Validation of the Artus Influenza RG PCR Test
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Each year the morbidity and mortality associated with respiratory tract infections fluctuates seasonally. This rise and fall is associated with the changing prevalence of respiratory viruses in the population. Myriad respiratory viruses are responsible for these infections. For example, Influenza Virus, Respiratory Syncytial Virus (RSV), Parainfluenza Virus, Human Metapneumovirus, Rhinovirus, and Adenovirus have all been identified as causing such infections. Numerous pathogenic subtypes have been identified within most of these viral groups. Apart from supportive measure (e.g., bed rest, hydration, etc.), there are no effective treatments for these viral infections; however, antiviral agents (e.g.,Tamiflu) can be used to alleviate the severity of flu-like symptoms.
Each year the virus population fluctuates, and with it the antigenic presentation of the dominant strains that circulate through the population. Epidemics arise when larger and larger portions of the population do not have innate or acquired resistance to such strain(s) in a given season. The World Health Organization (WHO) maintains a separate website dedicated to tracking outbreaks of influenza, especially avian influenza (https://www.who.int/fluvirus_tracker). Influenza outbreaks monitored in the hope that a pandemic similar to the Spanish Flu of 1918 can be avoided; it is estimated that well over 25 million people died from the Spanish Flu. The United States government also maintains a separate website with resources regarding the flu and pandemic related information (http://www.pandemicflu.gov/). On June 11, 2009 the WHO raised the pandemic threat level to 6 in response to the global appearance of a new strain of swine Influenza A (subtype H1N1). The rapidity with which the H1N1 virus has spread exemplifies the notion that quickly and accurately identifying a viruses associated with an outbreak is critical to global public health.
In the present study a collection of respiratory specimens that are well characterized will be archived for later evaluation using the artus® Influenza RG PCR test. The artus Influenza test is a real-time PCR test that identifies Influenza A, Influenza B, and Influenza Type A/subtype H1N1 from nasopharyngeal swab specimens.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85719
- University of Arizona
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- The University of North Carolina at Chapel Hill
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43210
- Ohio State University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Subjects that sign the Informed Consent form required for prospectively enrolling patients into the study.
- Subjects that present at a hospital, clinic, or physician's office with symptoms of a respiratory tract infection.
- Subjects with an acute respiratory infection where said acute respiratory infection is suspected of being caused by an Influenza virus.
Exclusion Criteria:
- Subjects where the duration of the symptoms of such an acute respiratory infection is greater than or equal to 7 days (i.e., ≥7).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
---|
Symptomatic
Individuals with signs and symptoms of a respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Presence of Influenza Virus
Délai: Specimens will be taken within 7 days of the appearance of symptoms.
|
To confirm the presence of Influenza virus in nasopharyngeal specimens taken from individuals having influenza like symptoms.
|
Specimens will be taken within 7 days of the appearance of symptoms.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- C09-INFLUENZA-002
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Grippe
-
Mitsubishi Tanabe Pharma CorporationComplété
-
Jiangsu Province Centers for Disease Control and...Royal (Wuxi) Biological Co., LTDComplétéGroupe A, C Méningite polysaccharidique | Haemophilus Influenza de type bChine
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.Complété
-
University Hospital, LilleCSL Behring; Laboratoire français de Fractionnement et de Biotechnologies; O... et autres collaborateursRésiliéInfections pneumococciques | Pneumonie bactérienne | Méningite bactérienne | Otite moyenne | Infection chronique des sinus | Infection streptococcique | Déficit en anticorps | Carence en complément | Infections à Neisseria | Haemophilus InfluenzaFrance
-
QIAGEN Gaithersburg, IncComplétéInfections par le virus respiratoire syncytial | Grippe A | Rhinovirus | Grippe B | Panneau avancé QIAGEN ResPlex II | Infection due au virus parainfluenza humain 1 | Parainfluenza de type 2 | Parainfluenza de type 3 | Parainfluenza de type 4 | Métapneumovirus humain A/B | Virus/échovirus Coxsackie | Adénovirus... et d'autres conditionsÉtats-Unis